KFU. Card publication. Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)

KAZAN
FEDERAL UNIVERSITY

- RUS
- 中文
- ES

TUMOR-TARGETED DRUG CONJUGATES AS AN EMERGING NOVEL THERAPEUTIC APPROACH IN SMALL CELL LUNG CANCER (SCLC)

Form of presentation

Articles in international journals and collections

Year of publication

2019

��

��

Authors, employees of KFU

Bumber Yanis Alekseevich, author

Deneka Aleksandr Yaroslavovich, author

Other authors

Beck Tim , author

Golemis Erica , author

Bibliographic description in the original language

Deneka A.Y. Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)/ A.Y. Deneka, Y. Boumber, T. Beck, E.A. Golemis // Cancers.-2019. -V.11, Is.9. doi: 10.3390/cancers11091297

Annotation

Cancers

Keywords

small cell lung cancer; antibody-drug conjugates; targeted therapy

The name of the journal

Cancers

Please use this ID to quote from or refer to the card

https://repository.kpfu.ru/eng/?p_id=220757&p_lang=2

Resource files

File name	Size (MB)	Format
12._SCLC_Review._Cancers_11_01297.pdf	1,15	pdf	show / download

Full metadata record

Field DC	Value	Language
dc.contributor.author	Bumber Yanis Alekseevich	ru_RU
dc.contributor.author	Deneka Aleksandr Yaroslavovich	ru_RU
dc.contributor.author	Beck Tim	ru_RU
dc.contributor.author	Golemis Erica	ru_RU
dc.date.accessioned	2019-01-01T00:00:00Z	ru_RU
dc.date.available	2019-01-01T00:00:00Z	ru_RU
dc.date.issued	2019	ru_RU
dc.identifier.citation	Deneka A.Y. Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)/ A.Y. Deneka, Y. Boumber, T. Beck, E.A. Golemis // Cancers.-2019. -V.11, Is.9. doi: 10.3390/cancers11091297	ru_RU
dc.identifier.uri	https://repository.kpfu.ru/eng/?p_id=220757&p_lang=2	ru_RU
dc.description.abstract	Cancers	ru_RU
dc.description.abstract	There are few effective therapies for small cell lung cancer (SCLC), a highly aggressive disease representing 15% of total lung cancers. With median survival <2 years, SCLC is one of the most lethal cancers. At present, chemotherapies and radiation therapy are commonly used for SCLC management. Few protein-targeted therapies have shown efficacy in improving overall survival; immune checkpoint inhibitors (ICIs) are promising agents, but many SCLC tumors do not express ICI targets such as PD-L1. This article presents an alternative approach to the treatment of SCLC: the use of drug conjugates, where a targeting moiety concentrates otherwise toxic agents in the vicinity of tumors, maximizing the differential between tumor killing and the cytotoxicity of normal tissues. Several tumor-targeted drug conjugate delivery systems exist and are currently being actively tested in the setting of SCLC. These include antibody-drug conjugates (ADCs), radioimmunoconjugates (RICs), small molecule-drug conjugates (SMDCs), and polymer-drug conjugates (PDCs). We summarize the basis of action for these targeting compounds, discussing principles of construction and providing examples of effective versus ineffective compounds, as established by preclinical and clinical testing. Such agents may offer new therapeutic options for the clinical management of this challenging disease in the future.	ru_RU
dc.language.iso	ru	ru_RU
dc.subject		ru_RU
dc.title	Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)	ru_RU
dc.type	Articles in international journals and collections	ru_RU